

# PCT ENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:  
HENRY D. COLEMAN  
COLEMAN SUDOL SAPONE, P.C.  
714 COLORADO AVENUE  
BRIDGEPORT, CT 06605-1601

# PCT

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing  
(day/month/year) **05 APR 2005**

Applicant's or agent's file reference  P27-051PCT		<b>FOR FURTHER ACTION</b> See paragraph 2 below	
International application No..  PCT/US04/09506	International filing date (day/month/year)  26 March 2004 (26.03.2004)	Priority date (day/month/year)  26 March 2003 (26.03.2003)	
International Patent Classification (IPC) or both national classification and IPC  IPC(7): C07C 229/00 and US Cl.: 560/9, 10, 15, 16, 19, 37, 38, 41, 47, 100, 103, 105,; 562/ 405, 426, 427, 422, 441, 442, 443, 490,			
Applicant  PURDUE RESEARCH FOUNDATION			

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application


2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/ US  Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer  Karl J. Ruttitz  Telephone No. (703) 308-1235
--	---

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/US04/09506

**Box No. I Basis of this opinion**

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

This opinion has been established on the basis of a translation from the original language into the following language \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

a sequence listing  
 table(s) related to the sequence listing

b. format of material

in written format  
 in computer readable form

c. time of filing/furnishing

contained in international application as filed.  
 filed together with the international application in computer readable form.  
 furnished subsequently to this Authority for the purposes of search.

3.  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.  
PCT/US04/09506

**Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Claims <u>4, 5, 7, 8, 10-12, 15, 21 and 23-38</u>	YES
	Claims <u>1-3, 6, 9, 13, 14, 16, 17, 18, 19, 20 and 22</u>	NO
Inventive step (IS)	Claims <u>4, 5, 7, 8, 10-12, 15, 21 and 23-38</u>	YES
	Claims <u>1-3, 6, 9, 13, 14, 16, 17, 18, 19, 20 and 22</u>	NO
Industrial applicability (IA)	Claims <u>1-38</u>	YES
	Claims <u>NONE</u>	NO

**2. Citations and explanations:**

Claims 1-3, 6, 9, 13, 14, 16, 17, 18, 19, 20 and 22 lack novelty under PCT Article 33(2) as being anticipated by Gibbs et al. This reference teaches compound registry no. 148101-36-4P, which anticipates the compounds of the rejected claims.

Claims 1-3, 6, 9, 13, 14, 16, 17, 18, 19, 20 and 22 novelty under PCT Article 33(2) as being anticipated by Ma et al. This reference teaches compound registry nos. 147263-95-4P and 156743-28-1P, which anticipate the compounds of the rejected claims.

Claims 1-3, 6, 9, 13, 14, 16, 17, 18, 19, 20 and 22 lack novelty under PCT Article 33(2) as being anticipated by Xu et al. This reference teaches compound registry nos. 147263-95-4P, which anticipates the compounds of the rejected claims.

Claims 4, 5, 7, 8, 10-12, 15, 21 and 23-38 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the compounds and methods covered by these claims.

Claims 1-38 the criteria set out in PCT Article 33(4), and thus claims 1-38 have industrial applicability because the subject matter claimed can be made or used in industry, such as therapeutic agents.